Francesc Sorio-Vilela
Overview
Explore the profile of Francesc Sorio-Vilela including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
82
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sicras-Mainar A, Sorio-Vilela F, Sacrest-Soy M, Gatell S, Sicras-Navarro A, Villoro-Valdes R, et al.
Rheumatol Ther
. 2025 Feb;
PMID: 39932674
Introduction: Postmenopausal osteoporosis (PMO) increases the risk of fragility fractures (FF), leading to disability, higher mortality, and elevated healthcare costs. Despite available treatments, osteoporosis (OP) remains undertreated, especially in women...
2.
Escobar-Cervantes C, Villa G, Campos-Tapias I, Sorio-Vilela F, Lozano J, Kahangire D, et al.
Adv Ther
. 2022 Jun;
39(8):3578-3588.
PMID: 35689725
Introduction: There is little evidence on the relationship between achieved low-density lipoprotein cholesterol (LDL-C) levels and costs in patients on lipid-lowering therapy (LLT). We described healthcare resource use and costs...
3.
Bruckert E, Desamericq G, Khachatryan A, Ngo P, Gusto G, Sorio-Vilela F
Rev Cardiovasc Med
. 2021 Jan;
21(4):643-650.
PMID: 33388010
Despite dyslipidaemia management guidelines, many patients do not reach low-density lipoprotein cholesterol targets due to insufficiently intensive regimens or lack of adherence to their medication. This was a retrospective cohort...
4.
Katzmann J, Sorio-Vilela F, Dornstauder E, Fraas U, Smieszek T, Zappacosta S, et al.
Clin Res Cardiol
. 2020 Sep;
111(3):243-252.
PMID: 32949286
Background: Many patients at very-high atherosclerotic cardiovascular disease risk do not reach guideline-recommended targets for LDL-C. There is a lack of data on real-world use of non-statin lipid-lowering therapies (LLT)...
5.
Forbes C, Deshpande S, Sorio-Vilela F, Kutikova L, Duffy S, Gouni-Berthold I, et al.
Curr Med Res Opin
. 2018 May;
34(9):1613-1625.
PMID: 29770718
Objectives: A systematic literature review was conducted comparing different approaches estimating persistence and adherence in chronic diseases with polypharmacy of oral and subcutaneous treatments. Methods: This work followed published guidance...